PipelineReview.com10h
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
LAUSANNE, Switzerland I 17, 2024 I AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for ...
PipelineReview.com13h
WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024
BARCELONA, Spain I 16, 2024 I WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive ...
PipelineReview.com13h
MinervaX and Wacker Biotech Announce Manufacturing Collaboration for Prophylactic Vaccine Targeting Group B Streptococcus
COPENHAGEN, Denmark and MUNICH, Germany I September 17, 2024 I MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic ...
PipelineReview.com13h
Mindpeak Announces Collaboration With Roche to Enhance Cancer Diagnostics Through AI
HAMBURG, Germany I 16, 2024 I Mindpeak announces its collaboration with Roche that will integrate Mindpeak's innovative AI algorithm with Roche’s ...
PipelineReview.com1d
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
– TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) – For children aged 5-11 years TransCon CNP demonstrated a change from ...
PipelineReview.com1d
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates
Partnership leverages Korro’s proprietary OPERA TM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; initially for cardiometabolic diseases Total deal value of up ...
PipelineReview.com1d
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
BELTSVILLE, MD, USA I September 16, 2024 I NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class ...
PipelineReview.com1d
ESMO 2024 – ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
SHENZHEN, China I September 15, 2024 I ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk ...
PipelineReview.com1d
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
INGELHEIM, Germany I 16, 2024 I Boehringer Ingelheim announced today that the FIBRONEER™-IPF trial met its primary endpoint, which was the ...
PipelineReview.com1d
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
COPENHAGEN, Denmark I September 16, 2024 I Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing ...
PipelineReview.com1d
Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected
LEXINGTON, MA, USA I 16, 2024 I Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, ...
PipelineReview.com1d
Trishula Therapeutics Presents Positive Results from Phase 1 Trial of TTX-030 in First-Line Metastatic Pancreatic Cancer Patients
SOUTH SAN FRANCISCO, CA, USA I 16, 2024 I Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today reported final results from a Phase 1 trial of TTX-030, a potential ...